Global Payments Inc vs Inovio Pharmaceuticals Inc — how do they compare? Global Payments Inc trades at $88.32 (market cap $22.72B), while Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M). The key difference: Global Payments Inc is far larger — about 289.2× Inovio Pharmaceuticals Inc's market cap, and Global Payments Inc pays a 1.16% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GPN | INO | |
|---|---|---|
Market Cap | $22.72B | $78.55M |
Sector | Industrials | Health |
52-Week High | $90.01 | $2.87 |
52-Week Low | $62.47 | $0.66 |
Enterprise Value | $40.87B | $49.56M |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $88.65, up 2.93% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 63.91% gross margin but negative net income margin and ROE. Recent Q2 2026 EPS of $3.46 beat estimates, though revenue guidance was trimmed. Analyst consensus is a Buy with a $96.67 target.
GPN offers upside to analyst targets but faces risks from margin pressure and competitive fintech landscape. Debt-to-asset ratio rose to 41.57% in 2025, increasing financial leverage concerns. Investment appeal hinges on execution of the Genius platform strategy amid economic headwinds.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Trailing returns across standard periods
Latest headlines on both assets
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →